Table 1.
Clinicopathologic parameters of two biopsy methods
| Saturation Biopsy (N = 106) | Twelve-core Biopsy (N = 269) | P Value | |
|---|---|---|---|
| Median age at diagnosis (IQR) | 59 (56, 63) | 60 (54-65) | .864 |
| Race (%) | |||
| African American | 7 (6.6) | 52 (19.3) | .002* |
| Other | 94 (88.7) | 201 (74.7) | |
| Unknown | 5 (4.7) | 16 (5.9) | |
| Median ng/mL prebiopsy PSA (IQR) | 4.6 (3.1, 7.1) | 5.4 (4.2, 8.3) | .017* |
| Median mL prostate volume (IQR) | 42 (31, 57) | 36 (28, 50) | .022* |
| No. of cT2 cases (%) | 13 (12.3) | 64 (26.6) | .003* |
| Biopsy | |||
| No. of Gleason (%) | |||
| G3 only | 53 (50.0) | 137 (50.9) | .871 |
| G ≥ 4 detected | 53 (50.0) | 132 (49.1) | |
| No. of positive cores (IQR) | 3 (2, 6) | 3 (2, 5) | .143 |
| Max cancer % of cores (IQR) | 40 (17, 60) | 40 (20, 70) | .254 |
| RP | |||
| Median g prostate weight (IQR) | 54 (44, 66) | 46 (38, 57) | <.001* |
| No. of Gleason (%) | |||
| G3 only | 37 (34.9) | 82 (30.5) | .407 |
| G ≥ 4 detected | 69 (65.1) | 187 (69.5) | |
| No. of pT stage (%) | |||
| pT2 | 84 (79.2) | 197 (73.2) | .226 |
| pT3 | 22 (20.8) | 72 (26.8) | |
| % Tumor volume (IQR) | 10 (5, 20) | 12 (5, 20) | .043* |
| No. of pN stage (%) | |||
| pN1 | 1 (0.9) | 2 (0.7) | .721 |
| pN0 | 97 (91.5) | 181 (67.3) | |
| pNx | 8 (7.5) | 86 (32.0) | |
| Margin status (%) | |||
| Positive | 22 (20.8) | 75 (27.9) | .098 |
| Negative | 84 (79.2) | 194 (72.1) |
IQR, interquartile range; RP, radical prostatectomy; PSA, prostate-specific antigen.
*
P < .05 considered statistically significant.